Notably, patients on GLP-1 RAs exhibited a 195% higher risk of major depression, a 108% increased risk for anxiety, and a 106% elevated risk for suicidal behavior
This means the FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they are marketed." (Source: FDA "Compounding and the FDA: Questions and Answers".) Clinical efficacy data such as the 14.9% mean weight loss from the STEP 1 trial or the 22.5% from SURMOUNT-1 comes from studies of the FDA-approved formulations, not from compounded versions
A 2024 phase 2 RCT by Hansen et al
The actress wrote: 'Ultimately, the main reasons why I will be chubby for life are (1) I have virtually no hobbies except dieting
Incorporation of a carboxylic acid moiety provided considerable GLP-1R potency gains with improved off-target pharmacology and reduced metabolic clearance, ultimately resulting in the identification of danuglipron